Testing effectiveness (Phase 2)Looking for participantsNCT05319730
What this trial is testing
Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Who this might be right for
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 230